JPMorgan analyst Alexei Gogolev downgraded Enfusion (ENFN) to Underweight from Neutral with a price target of $9, down from $11. The analyst prefers shares of SS&C (SSNC) to Enfusion given the company’s exposure to larger clients. Enfusion’s clients, which tend to be smaller hedge funds, are at risk of losing clients being consolidated under bigger money managers, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENFN: